A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

PHASE3CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 6, 2022

Primary Completion Date

July 14, 2025

Study Completion Date

August 13, 2025

Conditions
Lung Diseases, Interstitial
Interventions
DRUG

Nintedanib (Ofev®)

Nintedanib (Ofev®) soft capsules

Trial Locations (28)

1020

Brussels - UNIV HUDERF, Brussels

10021

Weill Cornell Medicine-New York-60569, New York

15224

Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

22081

Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg

33520

Tampere University Hospital, Tampere

37232

Vanderbilt University Medical Center, Nashville

41013

Hospital Virgen del Rocío, Seville

50139

Azienda Ospedaliera Meyer, Florence

54055

Clinical Research Institute S.C., Tlalnepantla

54642

"General Hospital of Thessaloniki Ippokrateio", Thessaloniki

80045

Children's Hospital Colorado, Aurora

90027

Children's Hospital Los Angeles, Los Angeles

94010

HOP Intercommunal, Créteil

27323240

Serviços Medicos Respirar Sul Fluminense, Barra Mansa

C1245AAM

Hospital de Pediatria Prof. Dr. Juan P. Garrahan, CABA

C1425EFD

Hospital de Niños Dr. Ricardo Gutierrez, CABA

5403-900

Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP, São Paulo

V6H 3N1

BC Children's Hospital, Vancouver

M5G 1X8

The Hospital for Sick Children, Toronto

150 06

Teaching Hospital Motol, Oncology Clinic, Prague

00165

Osp. Pediatrico Bambin Gesù, Roma

N-0372

Oslo Universitetssykehus HF, Rikshospitalet, Oslo

02091

Independent Public Teaching Children's Hospital, Warsaw

1169-045

ULS de São José, E.P.E. - Hospital Dona Estefânia, Lisbon

1649-035

ULS de Santa Maria, E.P.E, Lisbon

08035

Hospital Universitari Vall D Hebron, Barcelona

SE5 9RS

King's College Hospital, London

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05285982 - A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON) | Biotech Hunter | Biotech Hunter